期刊文献+

十一味益肾降糖片对Ⅲ期糖尿病肾病大鼠肾损伤干预的实验研究 被引量:2

Experiment Study on Shiyiwei Yishen Jiangtang Tablet on Kidney Damage of Ⅲ Stage DN Rats
下载PDF
导出
摘要 目的:探讨十一味益肾降糖片对Ⅲ期糖尿病肾病(DN)大鼠肾损伤的干预作用。方法:采用高糖高脂饮食加链脲佐菌素(STZ)腹腔注射的方法建立Ⅲ期DN大鼠模型,设立空白组(A组)、模型组(B组)、十一味益肾降糖片组(C组)、厄贝沙坦治疗组(D组)。灌胃12周后,检测各组大鼠空腹血糖(FBG)、肾肥大指数(KW/BW)、24 h尿蛋白定量(24-hrUP)、血清胱抑素(CysC)、肾小球硬化指数等指标,取右肾制作病理切片,观察肾脏病理改变。结果:十一味益肾降糖片可改善DN大鼠的一般状况,降低FBG、KW/BW、24-hrUP、CysC等指标;抑制肾小球毛细血管基底膜增厚、系膜基质增生及细胞外基质合成。结论:十一味益肾降糖片可降低Ⅲ期DN大鼠FBG、KW/BW、24-hrUP、CysC等指标;减轻肾脏病理损害,保护肾脏功能。 Objective:To discuss the intervention effect of Shiyiwei Yisben Jiangtang Tablet on kidney damage of m stage DN rats. Methods:The DN rat model was established by high suger and high fat food with STZ injection in abdomen. There were blank group( A group), model group ( B group ), Shiyiwei Yishen Jiangtang Tablet group ( C group ), Irbesartan group ( D group ). 12 weeks after gavage ,FBG, KW/BW ,24 -hrUP, CysC and other factors were detected and the pathological changes were observed. Results : Shiyiwei Yishen Jiangtang Tablet can relieve the common conditions of DN rats and reduce FBG, KW/BW, 24 - hrUP, CysC and other factors. It also can inhibit glomerular basement membrane thickening mesangial matrix proliferation and extracellular matrix synthesis. Conclusion:Shiyiwei Yishen Jiangtang Tablet can reduce FBG, KW/BW,24 -hrUP, CysC and other factors of DN rats in Ⅲ stage,relieve kidney damage and protect kidney functions.
作者 闫镛 付永祥
机构地区 开封市中医院
出处 《辽宁中医杂志》 CAS 2014年第7期1524-1525,I0002,共3页 Liaoning Journal of Traditional Chinese Medicine
基金 河南省科技发展计划(082102310034) 开封市级科研基金项目(110803)
关键词 十一味益肾降糖片 糖尿病肾病 肾损伤 Shiyiwei Yishen Jiangtang Tablet DN kidney damage
  • 相关文献

参考文献4

二级参考文献16

  • 1杨天崙,贺琳,李传昶,蒲晓群,郑昭芬,邓金华,孟双媛.冠心病患者血清同型半胱氨酸与冠脉侧支循环的关系[J].中南大学学报(医学版),2006,31(5):655-658. 被引量:8
  • 2吴晓莲.血清胱抑素C对2型糖尿病肾损伤的早期诊断意义[J].浙江中西医结合杂志,2007,17(8):493-494. 被引量:19
  • 3Kelly PJ, Rosand J. Homoeysteine, MTHFR 677C - T polymorphism, and risk of ischemie stroke: results of a meta- analysis[J]. BMJ, 2002,59 : 529 - 536.
  • 4Wald DS, Law M, Morros JK. Homocysteine and cardiovascular dis ease: evidence on causality from a meta - analysis[J]. BMJ, 2002, 32 (5) :1202- 1208.
  • 5Lazzerini PE, Capecchi PL, Selvi E, et al. Hyperhomocysteinemia: a cardiovascular risk factor in autoimrnune diseases[ J ]. Lupus, 2007,16: 852 - 862.
  • 6Hillenbrand R, Hillenbrand A, Liewald F, et al. Hyperhomocysteinemia and recurrent carotid stenosis[J]. BMC Cardiovasc Disord, 2008,8:1 - 2.
  • 7Ozemen B, Ozemen D, Turgan N, et al. Association between homocysteinemia and real function in patients with type 2 diabetes mellitus [J]. Ann Clin Lab Sci, 2002,32:279- 286.
  • 8Lentz SR. Homocysteine and cardiovascular physiology [M]. Cambridge: Cambridge University Press, 2001. 441-450.
  • 9Hucks D, Thuraisingham RC, Raftery MJ, et al. Homccysteine induced impairment of nitric oxide - dependent vasorelaxation is reversible by the superoxide dismutase mimetic TEMPOL [ J ]. Nephrol Dial Transp lant, 2004, 19: 1999-2005.
  • 10Kerkeni M. Hyperhomocysteinemia, paraoxonase concentration and cardiovascular complications in Tunisian patients with nondiabetic renal disease, Clin[J]. Biochem,2009,2(9) :6 - 12.

共引文献80

同被引文献26

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部